North America Whole Genome Sequencing Market to Grow Significantly During 2024-2031, Driven by Advancements in Precision Medicine and Genomic Research | DataM Intelligence

The Global Whole Genome Sequencing market size was valued at approximately USD 3.44 billion in 2023 and is expected to reach around USD 14.12 billion by 2031, growing at a CAGR of about 19.3% during the forecast period 2024-2031.

Market growth is driven by increasing demand for precision medicine, advancements in sequencing technologies, government support for genomic research, and rising applications in oncology and genetic disease diagnostics. North America holds the largest market share due to established genomics research infrastructure and favorable regulatory environment. The pharmaceutical and biotechnology sectors are key end-users, fueling adoption and innovation in whole genome sequencing.

United States: Key Industry Developments

✅ September 2025: The global whole genome sequencing market size projected to reach around USD 2.63 billion in 2025, with an expected CAGR of 22.2% till 2034, driven by clinical adoption and sequencing technology advancements.

✅ August 2025: BCC Research forecasted the market to grow from USD 3 billion in 2025 to USD 6.1 billion by 2030, at a CAGR of 15.1%, driven by personalized medicine and NGS innovations.

✅ July 2025: Expansion in bioinformatics and cloud-based genomic data analysis platforms accelerated, enabling scalable data management and interpretation.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/whole-genome-sequencing-market?ram

Japan: Key Industry Developments

✅ October 2025: Japan invested heavily in national genomic databases and public health genomics programs, boosting infrastructure for genomic sequencing and data sharing.

✅ Mid-2025: Increased government support for next-generation sequencing infrastructure and genomic research projects foster innovation and clinical integration.

✅ Early 2025: Rising collaborations between pharmaceutical companies, research institutes, and sequencing technology providers enhance genomic medicine adoption.

Mergers and Acquisitions (2025):

✅ Growth drivers include increased research on genetic mutations linked to cancers, rare diseases, and infectious illnesses, along with declining sequencing costs and expanding clinical applications such as personalized medicine and prenatal testing.

✅ Governments and healthcare organizations worldwide, such as the NHS in the UK, are investing in genomic data banks and incorporating WGS in disease diagnosis and treatment monitoring.

✅ Leading companies are focusing on enhancing sequencing technologies, automating workflows, and expanding genomics services in research institutes, hospitals, and pharmaceutical firms.

Growth Drivers:

-Increasing adoption of genomic medicine, rising demand for personalized therapies, and technological advancements in sequencing platforms drive market growth.

-North America leads the market with over 51.9% share in 2023 due to strong research infrastructure, clinical genomics ecosystems, and favorable reimbursement policies.

-Asia-Pacific is the fastest-growing region with a CAGR of 25.4%, propelled by large-scale genomics initiatives in China, India, and Japan, and expanding next-generation sequencing infrastructure.

-Growth is supported by expanding government-funded genomic programs, democratization of sequencing technologies, and increasing use of bioinformatics and AI tools for data analysis.

-The market is expanding across applications including clinical genomics, cancer research, rare disease diagnosis, and population-scale genetic studies, with key players investing heavily in automation and high-throughput sequencing solutions.

Market Segmentation Analysis:

-By Product

Instruments: Sequencers and ancillary laboratory equipment form a sizable portion, enabling high-throughput and automation in sequencing workflows.

Consumables: Including reagents, kits, and sequencing chips, these are the largest revenue contributors due to recurring usage in genome sequencing processes.

Services: Encompassing sequencing services, bioinformatics analysis, and data storage, growing with rising outsourcing trends.

-By Application

Diagnostics: The largest application segment leveraging WGS for rare disease diagnosis, oncology, and infectious disease profiling.

Drug Discovery: Utilizes WGS for target identification, biomarker discovery, and personalized drug development pathways.

Precision Medicine: Personalized treatment plans informed by comprehensive genomic data drive this fast-growing segment.

Epidemiological Studies: Use WGS extensively for pathogen surveillance and population genetics research.

Others include agriculture genomics, ancestry testing, and forensic applications.

-By Type

Large Whole Genome Sequencing accounts for approximately 58.6% of market revenue, regarded as the gold standard for exhaustive genetic information used in population-scale research and broad clinical applications.

Small Whole Genome Sequencing shows a high CAGR (~24.7%) owing to specialized applications such as neonatal diagnostics, pathogen sequencing, and targeted clinical labs.

-By End User

Academic & Research Institutes are the dominant users focused on genomics research and method development.

Hospitals and Diagnostic Centers are rapidly adopting WGS clinically for patient care and genetic counseling.

Pharmaceutical & Biotechnology Companies employ WGS in drug development and clinical trials.

Others include government agencies, public health organizations, and consumer genomics companies.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=whole-genome-sequencing-market?ram (Purchase 2 or more Reports and get 50% Discount)

Report Highlights:

69 Tables
69 Figures
184 Pages of Analysis

Regional Insights:

United States

-The U.S. whole genome sequencing (WGS) market is estimated at around USD 1.3 billion in 2024.

-It is projected to grow at a CAGR of 20-22% from 2025 to 2035, reaching a market size of approximately USD 11-13 billion by 2035.

-Growth drivers include increasing adoption of WGS in precision medicine, oncology, infectious disease management, and population genomics.

-The U.S. hosts major industry players and government-funded genomic research initiatives, accelerating technology adoption and cost reductions.

Japan

-Japan's WGS market is smaller but expanding steadily, supported by government policies promoting genomic medicine integration in healthcare.

-Investments in NGS platforms, clinical applications, and bioinformatics tools drive market growth.

-Aging population and rising chronic disease incidences further boost demand for genomic diagnostics.

Europe

-Europe accounts for a significant share with market size estimated near USD 600-700 million in 2024.

-Major countries include the UK, Germany, and France, with strong research infrastructure and increasing regulatory support for genomic testing.

-Growth is accelerated by public health genomics projects, cancer genome initiatives, and increasing clinical adoption of WGS technologies.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/whole-genome-sequencing-market?ram

Competitive Landscape:

According to DataM Intelligence, the Whole Genome Sequencing Market is rapidly expanding, driven by advancements in sequencing technologies, growing adoption in clinical and research applications, and increasing investments in personalized medicine and genetic research.

Key Players
Illumina, Inc. | Thermo Fisher Scientific, Inc. | Oxford Nanopore Technologies | QIAGEN | Agilent Technologies | PerkinElmer Genomics | Bio-Rad Laboratories, Inc. | F. Hoffmann-La Roche Ltd | PACBIO | PierianDx

Key Highlights (Top 5 Key Players)

-Illumina, Inc. leads the market with an estimated 35-38% share, supported by its dominant sequencing platforms and ongoing innovation in high-throughput, cost-effective genomic solutions.

-Thermo Fisher Scientific, Inc. holds around 20-22% share, bolstered by integration of gold-standard Sanger sequencing and scalable next-generation sequencing systems, including the Ion Torrent Genexus System for rapid specimen-to-report workflow.

-Oxford Nanopore Technologies commands approximately 10-12% share, known for its portable sequencing devices and long-read sequencing capabilities that enable real-time genomic analysis.

-QIAGEN captures near 8-10% market share through its specialized sample preparation kits and bioinformatics solutions that complement sequencing workflows.

-Agilent Technologies accounts for about 6-8%, focusing on advanced reagents and sequencing instruments to enhance accuracy and efficiency in genomic profiling.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.